US 12,449,413 B2
Method of assessing wound healing potency of a mesenchymal stem population and related methods of selecting mesenchymal stem cells and identifying tissue as starting material for producing a mesenchymal stem cell population
Toan Thang Phan, Singapore (SG)
Assigned to CELLRESEARCH CORPORATION PTE. LTD., Singapore (SG)
Filed by CELLRESEARCH CORPORATION PTE. LTD., Singapore (SG)
Filed on Oct. 8, 2020, as Appl. No. 17/066,378.
Claims priority of provisional application 62/912,374, filed on Oct. 8, 2019.
Prior Publication US 2021/0140942 A1, May 13, 2021
Int. Cl. G01N 33/50 (2006.01); C12N 5/00 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/5005 (2013.01) [C12N 5/0018 (2013.01); G01N 33/6803 (2013.01); G01N 2333/475 (2013.01); G01N 2333/4753 (2013.01); G01N 2333/495 (2013.01); G01N 2496/00 (2013.01)] 13 Claims
 
1. A method of assessing the wound healing potency of an amniotic membrane mesenchymal stem cell population and selecting a desired mesenchymal stem cell population having effective potency for wound healing, wherein the method comprises:
(a) cultivating the amniotic membrane mesenchymal stem cell population in vitro in a medium suitable for cultivation of an amniotic membrane mesenchymal stem cell population,
(b) determining in the medium the secretion level of each of Angiopoietin 1 (Ang-1), Transforming Growth Factor beta (TGF-B), Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF) secreted into the medium by the amniotic membrane mesenchymal stem cell population;
(c) comparing the determined secretion level of each of Ang 1, TGF β, VEGF, and HGF to a corresponding threshold level, and selecting a mesenchymal stem cell population having a secretion level of each of Ang 1, TGF β, VEGF, and HGF equaling or exceeding its corresponding threshold level to provide the desired mesenchymal stem cell population having effective potency for wound healing, wherein the threshold values are
a threshold value of at least 400 pg/ml for Angiopoietin 1 (Ang-1),
a threshold value of at least 400 pg/ml for Transforming Growth Factor beta (TGF-β),
a threshold value of at least 80 pg/ml for Vascular Endothelial Growth Factor (VEGF); and
a threshold value of at least 80 pg/ml for Hepatocyte Growth Factor (HGF), and
(d) placing the selected amniotic membrane mesenchymal stem cell population into
(i) a cultivation medium selected for cultivation the selected amniotic membrane mesenchymal stem cell population, or
(ii) a cryoprotectant medium selected for long term storage of the selected amniotic membrane mesenchymal stem cell population, or
(iii) a preservation medium selected for short term storage of the selected amniotic membrane mesenchymal stem cell population prior to administration to a subject.